HANGZHOU, China, Sept. 18, 2026 (GLOBE NEWSWIRE) — Since the beginning of September, CaoCao Inc. (2643.HK) has continued to expand its ecosystem of AI device partnerships. Following its launch on Doubao AI phones, CaoCao’s AI ride-hailing service officially integrated with HONOR YOYO on September 15 and received the “Innovative Partner” award at the 2026 HONOR Global Developer Conference. On September 17, CaoCao announced the integration of its AI ride-hailing service with OPPO Breeno Next.

Following the announcements, CaoCao’s shares extended their gains, rising more than 20% over two days.

With HONOR YOYO, users can simply state their ride needs. YOYO can automatically identify pickup and drop-off points, match users with CaoCao’s mobility resources, select an appropriate vehicle type and route, and complete the booking. In this collaboration, CaoCao opened up caocao-cli for the first time, a standard interface that enables AI agents to invoke CaoCao services, making CaoCao the first platform in the AI mobility sector to use CLI-based integration with on-device agents. The interface introduces a unique idempotency key, an explicit confirmation flag and a unified Trace ID, ensuring that network retries do not result in duplicate bookings, critical actions require user confirmation, and the entire service chain is traceable and auditable.

With OPPO Breeno Next, users can search for CaoCao’s AI agent, “Xiao Cao,” and state their ride needs in natural language. They can then compare fares across vehicle types, book a ride with one tap and track their trip directly within the interface. In this collaboration, CaoCao upgraded caocao-mcp, its unified standard protocol that enables AI agents to invoke CaoCao services, making CaoCao’s AI ride-hailing service the first AI mobility service in Breeno Next to support UI interaction. Depending on agent capabilities, caocao-mcp also supports multiple interaction formats, including text, web pages and interactive cards.

From Doubao AI phones to HONOR YOYO and OPPO Breeno Next, CaoCao’s AI ride-hailing service is becoming available across a growing range of endpoints. Building on its scalable, systematic capabilities in fleet dispatching, asset management, user services and compliance operations, CaoCao has enabled efficient connections between AI agents and mobility resources on its platform.

Contact:
Jing Liu   
Jing.Liu3@caocaoglobal.com

Press release – No. 16 / 2026

Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

  • The CHMP of the European Medicines Agency has recommended the approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
  • The positive CHMP opinion marks the first major advancement in short bowel syndrome treatment in Europe in more than a decade
  • Zeydovio’s™ evidenced efficacy combined with its simple delivery, positions it as a transformative therapy for people living with short bowel syndrome
  • Two thirds of patients treated with glepaglutide achieved a clinical response of at least a 20% reduction in weekly parenteral support volume, and one in seven weaned off parenteral support entirely, after 24 weeks of treatment
  • Zealand Pharma continues to advance glepaglutide toward patients globally with active enrolment into the Phase 3 EASE-5 trial to support a U.S. NDA


Copenhagen, Denmark, September 18, 2026
– Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for Zeydovio™ (glepaglutide), a long-acting, next-generation GLP-2 analog, for the treatment of adults with short bowel syndrome (SBS).

“The positive opinion for Zeydovio™ is the first major advancement in short bowel syndrome treatment in Europe in more than a decade. Those living with short bowel syndrome face significant daily burdens and are susceptible to significant health risks from parenteral support, and every day free from it can be life changing. In the Phase 3 trials, Zeydovio™ significantly reduced parenteral support volume, reducing the number of days required for many patients and eliminating the need for it entirely in others,” said David Kendall, MD, Chief Medical Officer of Zealand Pharma. “Offering simple dosing twice weekly via a ready-to-use autoinjector, Zeydovio™ holds potential as a transformative therapy for SBS that could meaningfully ease the burden of disease management for thousands of patients.”

The positive opinion is based on data from the pivotal Phase 3 EASE-1 trial, in which twice-weekly glepaglutide demonstrated statistically significant and superior reductions in parenteral support requirements in SBS patients with intestinal failure (IF) compared to placebo. These data were supported by interim results from the EASE-2 and EASE-3 trials, the long-term extension trials of up to two years, and results from a mechanistic trial (EASE-4) providing evidence of glepaglutide’s pharmacodynamic effects in improving intestinal absorption. In the clinical trials to date, glepaglutide treatment appeared safe and well tolerated. Results from the EASE-2 and EASE-3 trials, which confirmed the long-term efficacy and safety of glepagutide, are expected to be presented at scientific meetings in 2027.

The CHMP’s opinion will now be reviewed by the European Commission, with a final decision on the Marketing Authorization Application (MAA) expected within approximately 67 days. Subject to European Commission approval, the marketing authorization would be valid in all member states of the European Union, as well as Iceland, Liechtenstein, and Norway.

Zealand Pharma is actively engaging in partnership discussions for the future global commercialization of glepaglutide for SBS.

The Phase 3 EASE-5 trial, designed to provide further confirmatory evidence to support a regulatory submission in the U.S., is ongoing, with patient recruitment progressing well.

About short bowel syndrome
Short bowel syndrome (SBS) is a rare, chronic and severe disease associated with reduced or complete loss of intestinal function, leaving many patients chronically dependent on complex parenteral support (PS). While life-sustaining, parenteral support poses significant restrictions on patients’ ability to engage in daily activities. In addition, they are at risk of experiencing a number of serious and life-threatening complications such as sepsis, blood clots, liver damage and renal impairment.

About glepaglutide
Glepaglutide is a long-acting GLP-2 analog in development for the treatment of short bowel syndrome, aiming to reduce or eliminate the need for parenteral support by improving intestinal function. With its long half-life and high stability in aqueous solution, glepaglutide is developed for twice-weekly, subcutaneous administration via a ready-to-use, single-dose autoinjector. The U.S. FDA has granted orphan drug designation for glepaglutide for the treatment of SBS.

About the EASE Clinical Trial Program
The Phase 3 program, named EASE, is designed to evaluate the potential for glepaglutide to reduce or eliminate the need for PS in SBS patients with intestinal failure.

EASE-1 (NCT03690206) was a randomized, double-blind Phase 3 trial in 106 SBS patients with intestinal failure who were dependent on PS for at least three days per week. Patients were evenly randomized to receive glepaglutide 10 mg once or twice weekly, or placebo. The primary endpoint was the absolute change in weekly PS volume from baseline at 24 weeks. At 24 weeks, glepaglutide administered twice weekly significantly reduced the total weekly volume of PS by 5.13 liters/week compared to 2.85 liters/week in the placebo group (p=0.0039). Clinical efficacy was observed in patients with and without colon-in-continuity. Among patients receiving glepaglutide twice weekly, 65.7% achieved a clinical response, defined as at least 20% reduction in weekly PS volume at 24 weeks (versus 38.9% in the placebo group), and 51.4% of patients achieved a reduction in PS days of at least 1 day/week (versus 19.4% in the placebo group). Nine patients treated with glepaglutide were completely weaned off PS (achieving enteral autonomy), while no placebo-treated patients achieved enteral autonomy. For patients treated twice weekly, 14% (n=5) achieved enteral autonomy. Glepaglutide treatment appeared safe and well tolerated.

In total, 102 of 106 participating patients completed EASE-1, of which 96 continued into the two-year long-term safety and efficacy extension trial, EASE-2.

EASE-2 (NCT03905707) was a randomized, double-blind trial in which SBS patients continued their randomly assigned treatment from EASE-1 with glepaglutide 10 mg once- or twice-weekly. Patients who received placebo in EASE-1 were re-randomized to glepaglutide 10 mg once- or twice-weekly. In addition, a smaller group of patients not previously treated with glepaglutide were directly randomized to receive glepaglutide 10 mg once- or twice weekly. In an interim analysis after at least six months of treatment, clinical response across the key efficacy endpoints was generally maintained or showed continued improvement, including additional patients on both doses weaning off PS.

Patients who completed EASE-2 were eligible for EASE-3 (NCT04881825), evaluating glepaglutide administered once weekly using an autoinjector. The EASE-2 and EASE-3 trials were completed in 2026, and the remaining patients have rolled over to a new extension trial, EASE-6 (NCT07228403). Results from the EASE-2 and EASE-3 trials are expected to be presented at scientific meetings in 2027.

EASE-4 (NCT04991311) was a Phase 3b trial to assess mechanistic effects of glepaglutide once weekly on intestinal fluid and energy uptake, providing evidence of the pharmacodynamic effects of glepaglutide in improving intestinal absorption. The primary endpoint was absolute change in intestinal wet weight absorption. Secondary endpoints assessed changes in energy, electrolyte, and macronutrient absorption after 24 weeks of treatment. Additional endpoints included changes in PS use, body composition and safety after 52 weeks of treatment. At week 24, mean numerical increase in intestinal wet weight absorption was 398 g/day (p=0.0585) and mean energy absorption 1038 kJ/day (p=0.0215). Improvements occurred in electrolyte and macronutrient absorption. At week 52, mean PS volume was reduced by 800 mL/day (p=0.0106) with a reduction in mean PS energy content of 866 kJ/day (p=0.0103).

EASE-5 (NCT07197944) is a randomized, double-blind, placebo-controlled Phase 3 trial, designed to confirm the efficacy and safety of glepaglutide twice weekly, followed by a long-term, open-label safety evaluation in SBS patients with intestinal failure.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Forward looking statements 
This press release contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company’s pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

Zealand Pharma® is a registered trademark of Zealand Pharma A/S.

Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
erojas@zealandpharma.com

Neshat Anis Ahmadi (Investors)
Investor Relations Manager
neahmadi@zealandpharma.com

Rachel James-Owens (Media)
Vice President, Corporate Communications and Media Relations
RJamesOwens@zealandpharma.com

Andreas Hylleberg (Media)
Director, External Communications
Zealand Pharma
Email: AHylleberg@zealandpharma.com

Amber Fennell, Jessica Hodgson, and Sean Leous (Media)
ICR Healthcare
ZealandPharma@icrhealthcare.com
+44 (0) 7739 658 783

Transaction in Own Shares

September 17, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 17 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency
17/09/2026 1,175,000 £ 35.9250 £ 35.4750 £ 35.6929 LSE GBP
17/09/2026 – – – – Chi-X (CXE) GBP
17/09/2026 – – – – BATS (BXE) GBP
17/09/2026 600,000 € 42.0450 € 41.3850 € 41.6270 XAMS EUR
17/09/2026 – – – – CBOE DXE EUR
17/09/2026 – – – – TQEX EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026. 

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

 

Attachment

SAN JUAN CAPISTRANO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.0650 per share of Ensign common stock, payable on or before October 31, 2026, to shareholders of record as of September 30, 2026.

Ensign has been a dividend-paying company since 2002.

About Ensign™

The Ensign Group, Inc.’s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 398 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information

The Ensign Group, Inc., (949) 487-9500, ir@ensignservices.net

SOURCE: The Ensign Group, Inc.

FOSHAN, China, Sept. 18, 2026 (GLOBE NEWSWIRE) — Viomi Technology Co., Ltd (“Viomi” or the “Company”) (NASDAQ: VIOT), a leading global technology company for home water systems, today announced that it has received a written notification letter (the “Compliance Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated September 17, 2026, informing the Company that it has regained compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).

As previously announced on July 23, 2026, Viomi received a notification letter from Nasdaq indicating that the Company was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the Company’s American Depositary Shares (the “ADSs”) was below US$1.00 per ADS for 30 consecutive business days. According to the Compliance Notice, the closing bid price of the Company’s ADSs has been at US$1.00 per ADS or greater for 10 consecutive business days from September 2 to September 16, 2026, and the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is closed.

About Viomi Technology

Viomi’s mission is “AI for Better water,” utilizing AI technology to provide better drinking water solutions for households worldwide.

As an industry-leading technology company in home water solutions, Viomi has developed a distinctive “Equipment + Consumables” business model. By leveraging its expertise in AI technology, intelligent hardware and software development, the Company simplifies filter replacement and enhances water quality monitoring, thereby increasing the filter replacement rate. Its continuous technological innovations extend filter lifespan and lower user costs, promoting the adoption of water purifiers and supporting a healthy lifestyle while effectively addressing the rising global demand for cleaner, fresher and healthier drinking water. The Company operates a world-leading “Water Purifier Gigafactory” with an integrated industrial chain that boasts optimal efficiency and facilitates continuous breakthroughs in water purification. This state-of-the-art facility enables Viomi to achieve economies of scale and accelerate the global popularization of residential water filtration.

For more information, please visit: https://ir.viomi.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the estimated revenue and income from operations from the Continuing Businesses, the business outlook and quotations from management in this announcement, as well as Viomi’s strategic and operational plans, contain forward-looking statements. Viomi may also make written or oral forward-looking statements in its periodic reports to the United States Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s growth strategies; the cooperation with Xiaomi; recognition of the Company’s brand; trends and competition in the global IoT-enabled smart home market; the development and commercialization of new products, services and technologies; governmental policies and the relevant regulatory environment relating to the Company’s industry and/or aspects of its business operations; general economic conditions in China and around the globe; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

In China:

Viomi Technology Co., Ltd
Claire Ji
E-mail: ir@viomi.com.cn

Piacente Financial Communications
Jenny Cai
Tel: +86-10-6508-0677
E-mail: viomi@tpg-ir.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
E-mail: viomi@tpg-ir.com

Lassila & Tikanoja Plc
Stock exchange release
18 September 2026 at 12:30 PM EEST

Record date and payment date of Lassila & Tikanoja Plc’s second dividend instalment of EUR 0.21

In the Annual General Meeting of Lassila & Tikanoja Plc held on 28 April 2026, it was resolved that based on the balance sheet adopted for the financial year 2025, a dividend of EUR 0.42 per share shall be paid in two instalments, and that the record date and payment date of the second dividend instalment shall be resolved by the Board of Directors in its meeting scheduled for 18 September 2026.

The Board of Directors has today resolved that the dividend payment date for the second dividend instalment of EUR 0.21 per share will be 2 October 2026 and the dividend record date will be 22 September 2026 (originally on or about 1 October 2026 and 22 September 2026).

In accordance with the resolution of the Annual General Meeting, the first dividend instalment of EUR 0.21 per share was paid on 8 May 2026.

LASSILA & TIKANOJA PLC

Board of Directors

Joni Sorsanen
CFO

Additional information:
Joni Sorsanen, CFO, tel. +358 50 443 3045

Lassila & Tikanoja is a leading Nordic circular economy company committed to unleashing the potential of circularity together with its customers and partners. Our services include waste management and recycling, hazardous waste and remediation services as well as industrial services and water treatment. Our goal is to strengthen an efficient infrastructure in society and promote the sustainable use of materials by transforming waste streams into valuable raw materials. L&T employs approximately 2,300 people in Finland and Sweden and is listed on Nasdaq Helsinki.

Distribution:
Nasdaq Helsinki
Major media
www.lt.fi/en

#FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Rotork Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
17/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

0.5p ordinary
  Interests

Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled:        
(2)   Cash-settled derivatives:

15,045,090 1.84 11,271 0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        

        TOTAL:

15,045,090 1.84 11,271 0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale

Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
0.5p ordinary Equity swap Reducing a long position 1,773 4.8479 GBP
0.5p ordinary Equity swap Reducing a long position 1,771 4.8460 GBP

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 18/09/2026
Contact name: Graham Keene
Telephone number: +44 20 7144 2259

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Figure 1a

Highlights of Hole GD-26-431
Highlights of Hole GD-26-431

Figure 1b

Bonanza Zone cross section displaying GD-26-431 and other proximal holes from the same vein.
Bonanza Zone cross section displaying GD-26-431 and other proximal holes from the same vein.

Figure 1c

Geology cross section displaying GD-26-431.
Geology cross section displaying GD-26-431.

Figure 2a

Highlights of Hole GD-26-442
Highlights of Hole GD-26-442

Figure 2b

Geology cross section of Hole GD-26-442 and GD-26-426
Geology cross section of Hole GD-26-442 and GD-26-426

Figure 3

Plan view map highlighting the expansion of the Bonanza Zone thus far in 2026.
Plan view map highlighting the expansion of the Bonanza Zone thus far in 2026.

Figure 4a

Visible Gold to the Naked Eye (VG-NE)
Visible Gold to the Naked Eye (VG-NE)

Figure 4b

Visible Gold to the Naked Eye (VG-NE) cont’
Visible Gold to the Naked Eye (VG-NE) cont’

Figure 4c

Visible Gold to the Naked Eye (VG-NE) cont’
Visible Gold to the Naked Eye (VG-NE) cont’

Figure 4d

Visible Gold to the Naked Eye (VG-NE) cont’
Visible Gold to the Naked Eye (VG-NE) cont’

Figure 4e

Visible Gold to the Naked Eye (VG-NE) cont’
Visible Gold to the Naked Eye (VG-NE) cont’

Figure 5

Isometric View of the Surebet Discovery Ore Mineralization Model
Isometric View of the Surebet Discovery Ore Mineralization Model

Figure 6

Plan View Map of Surebet Discovery showing holes with VG-NE.
Plan View Map of Surebet Discovery showing holes with VG-NE.

 *For reported assay intervals and AuEq calculation please see QA/QC Section on page 16.

*For reported assay intervals and AuEq calculation please see QA/QC Section on page 16.

  • All drill holes from the 2026 drill program completed to date have intersected quartz-sulphide mineralization which typically coincide with high-grade gold mineralization.
  • Only a hand full holes with complete gold equivalent (AuEq) assays have been reported to date from a total of 97 drill holes for this year’s program; many more assays to come.
  • The fully funded 2026 drill program comprises approximately 50,000 meters of systematic drilling, including 7 drill rigs targeting expansion of the known gold mineralization laterally and at depth, focused on the Bonanza, Eldorado, Golden Gate, Surebet and Whopper Zones.

TORONTO, Sept. 18, 2026 (GLOBE NEWSWIRE) — Goliath Resources Limited (TSX-V: GOT) (OTCQX: GOTRF) (FSE: B4IF) (the “Company” or “Goliath”) is pleased to report assay results for drill holes GD-26-426, GD-26-431 and GD-26-442 from the Bonanza Zone at the Surebet Discovery on its 100% owned Golddigger Property (the “Property”), Golden Triangle, British Columbia. All reported holes contain substantial gold-mineralization characterized by the widespread presence of VG-NE that continues to demonstrate increased confidence in the continuity as well as the expansion potential of the Surebet High-Grade Gold System.

Dr. Quinton Hennigh, Advisor to Goliath and Strategic Investor commented: “When I see so many intercepts the likes of 9.12 gpt AuEq over 11.27 meters on the edge of a large system like Surebet, it clearly confirms there remains significant room for growth. This year’s drill program continues to deliver results that strongly indicate this high-grade gold system has room for expansion. In 2026 the Company used a systematic approach to drilling that already has demonstrated a significant increase in the overall size of this system that still remains open both laterally and to depth. I look forward to seeing further results such as this.”

Mr. Roger Rosmus, Founder & CEO of Goliath states: “We are pleasantly surprised that as we have focused on step out drilling during the 2026 drilling campaign to grow the dimensions of the Surebet system it has delivered. I think it is important to point out that we have not stepped out with narrow spacing of the holes like most high-grade vein systems require. We wanted to put the Surebet to test this year to see if we could get near the edges of the system, instead of finding the edges, the system is widening. Several of our step out holes have been 100 metres and up to 750 metres. The footprint of high-grade with visible gold just keeps getting larger which is rare to see. We have only reported a small handful of gold equivalent drill hole results to date, with the vast majority are pending assays. We look forward to reporting additional drill results as they become available, stay tuned.”

Drill Hole GD-26-431 (Pad 4, Azimuth 40, Dip 85) successfully intersected two distinct mineralized intervals within the Bonanza Zone along the western fringes of the system. The first interval returned high-grade results, assaying 9.12 g/t AuEq over 11.27 meters, which includes a higher-grade core of 13.89 g/t AuEq over 7.14 meters. Mineralization in this upper intercept consists of stockwork and breccia veins associated with calc-silicate and biotite alteration, featuring abundant VG-NE alongside galena, sphalerite, and pyrrhotite. The second deeper interval assayed 4.70 g/t AuEq over 3.03 meters, within a broader interval of 1.08 g/t AuEq over 20.00 meters where mineralization is hosted primarily in stockwork veins and veinlets accompanied by biotite-sericite alteration and pyrrhotite that is proximal to the new Big Bulk Zone.

Drill Hole GD-26-442 (Pad 15, Azimuth 310, Dip 79) targeted the northern 100 meter step-out expansion of the Bonanza Zone. This hole successfully intersected 8.35 g/t AuEq over 4.15 meters, which includes a high-grade interval of 31.42 g/t AuEq over a 1.00-meter core length. Mineralization in this zone is characterized by well-defined quartz-sulphide veins associated with localized biotite and sericite alteration, VG-NE, galena, sphalerite, and pyrrhotite.

Drill Hole GD-26-426 (Pad 15, Azimuth 310, Dip 79) tested a strategic 100 meter step-out interval of the Bonanza Zone to the north-northwest. This hole intersected a high-grade sub-interval of 5.07 g/t AuEq over 3.91 meters within a broader interval of 2.93 g/t AuEq over 7.00 meters. The intercept is defined by a sheared quartz breccia containing VG-NE, accompanied by massive to stringer concentrations of sphalerite, pyrrhotite, galena, and chalcopyrite.

Table 1: Gold and gold equivalent assay results.

Hole ID   From (m) To (m) Interval (m) Au (g/t) Ag (g/t) Cu % Pb % Zn % AuEq (g/t)
GD-26-431 Interval 372.20 388.21 16.01 6.34 5.31 0.01 0.06 0.15 6.48
Including 374.20 385.47 11.27 8.93 6.78 0.01 0.08 0.20 9.12
Including 374.20 381.34 7.14 13.71 6.38 0.01 0.08 0.22 13.89
Including 374.20 375.23 1.03 74.33 12.51 0.01 0.06 0.43 74.66
And 380.46 381.34 0.88 22.18 30.06 0.01 0.41 1.21 23.06
Interval 391.00 411.00 20.00 0.98 3.67 0.01 0.04 0.07 1.08
Including 396.94 407.90 10.96 1.58 4.47 0.01 0.06 0.11 1.70
Including 401.09 404.12 3.03 4.65 2.11 0.01 0.00 0.02 4.70
GD-26-442 Interval 529.00 533.15 4.15 7.33 41.80 0.01 1.23 0.60 8.35
Including 529.00 530.00 1.00 27.58 159.00 0.02 4.67 2.25 31.42
GD-26-426 Interval 585.00 592.00 7.00 2.64 7.77 0.01 0.17 0.51 2.93
Including 585.00 588.91 3.91 4.64 12.27 0.01 0.29 0.69 5.07
Including 587.12 588.00 0.88 19.90 29.65 0.02 0.82 2.06 21.05

*For reported assay intervals and AuEq calculation please see QA/QC Section on page 16

Table 2: Collar information for drill holes reported in this news release.

Hole ID CRS Easting (m) Northing (m) Elevation (m) Azimuth (deg) Dip (deg) Length (m)
GD-26-431 NAD83 / UTM zone 9N 456710 6162961 1639 40 85 489
GD-26-442 NAD83 / UTM zone 9N 457189 6163130 1704 310 79 600
GD-26-426 NAD83 / UTM zone 9N 457189 6163130 1704 310 79 642


Surebet Discovery Highlights

  • 100% of the drill holes completed prior to the 2026 drill season have intersected gold mineralization, clearly demonstrating remarkable grade continuity and widths, with over 1,500 diamond drill hole intercepts (pierce points); ~77% have 25 – 50 meter spacings. Demonstrating the geological team has a great understanding of the system and its predictability.
  • The most recent ore mineralization model incorporating all available data prior to the 2026 drill program identified five (5) stacked gold-mineralized vein systems/zones: Bonanza, Surebet, Golden Gate, Whopper, and Eldorado. Collectively these zones comprise 46 gold-rich lodes/veins and multiple subvertical Eocene-aged dyke swarms. A good analogy for the stacked veins that are gently-dipping is the Pogo Mine in Alaska. (see Table 3 and Figure 5).

Table 3: Five main modelled gold rich zones and dykes, see isometric view in Figure 5 below.

Zone Number of lodes/veins Dimensions Key Intercept Status
Bonanza 5 1.8 km x 1.8 km x 19 m 8.35 g/t AuEq over 23 m Remains Open
Surebet 9 1.2 km x 1.0 km x 19 m 21.08 g/t AuEq over 23 m Remains Open
Golden Gate 18 1.6 km x 1.5 km x 14 m 34.52 g/t AuEq over 39 m Remains Open
Whopper 12 1.0 km x 1.0 km x 6 m 32.67 g/t AuEq over 4 m Remains Open
Eldorado 2 1.0 km x 900 m x 5 m 13.93 g/t AuEq over 5.75 m Remains Open
Gold-rich dykes   1.4 km x 890 m x 25 m 12.03 g/t AuEq over 10 m Remains Open

  • 92% of the holes (355 out of 386) drilled prior to the 2026 drill season at Surebet contain VG-NE and 100% of holes drilled to date at the Surebet Discovery have intersected quartz-sulphide mineralization. See news releases dated: July 7, 2025, June 23, 2025, January 7, 2025, January 13, 2025, February 10, 2025, February 18, 2025, February 27, 2025, December 12, 2024, July 30, 2024, January 20, 2026, December 2, 2025, November 17, 2025, October 27, 2025, September 22, 2025, September 8, 2025, August 26, 2025, and July 28, 2025 (see Figure 6).
  • High-grade gold has been identified in three distinctive rock types, including: quartz-sulphide breccias and stockwork veins hosted in the sedimentary units; precious and base metals bearing veins hosted in the volcanic units; and intermediate to felsic Eocene-aged dykes. All mineralized rock types contain substantial amounts of VG-NE (from fine-grained to coarse-grained gold) and remain open for expansion.
  • Metallurgical testing conducted on a composite core sample resulted in metal recoveries of 92.2% for Au, 86.5% for Ag, 94.2% for Pb and 96.9% for Zn achieved through a combination of simple gravity and flotation circuits. The gravity-only recoveries amount to 48.8% Au and 10.3% Ag with a crush size of 327 micrometer (no cyanide leaching required to recover the gold and silver). The metallurgical testing completed to date shows a benign rock composition without deleterious elements (see news release March 1, 2023).
  • The consistent continuity, widths and grade of ore mineralization demonstrated by >156,000 meters of drilling in multiple stacked lodes/veins confirms that the 1.8 km2 Surebet Discovery continues to demonstrate strong potential to become one of the most significant high-grade gold discoveries in British Columbia’s Golden Triangle in many years.
  • The best hole drilled to date from the gold-rich stacked quartz-sulphide breccias and stockwork veins hosted in the sedimentary units is GD-23-157 that assayed 21.08 g/t AuEq (18.95 g/t Au and 95.31 g/t Ag) over 23.00 meters, including 33.75 g/t AuEq (30.39 g/t Au and 150.42 g/t Ag) over 14.00 meters, including 50.27 g/t AuEq (45.27 g/t Au and 225.42 g/t Ag) over 9.00 meters (see news release dated August 15, 2023). More details on the QA/QC protocol can be found in the section titled “QA/QC Protocol” below.
  • The best hole drilled to date from the precious and base metals bearing veins hosted in the volcanic units is GD-24-260 from the Golden Gate Zone that assayed 34.52 g/t AuEq (34.47 Au and 3.96 Ag) over 39.00 meters, including 132.93 g/t AuEq (132.78 Au and 12.98 Ag) over 10.00 meters, and 166.04 g/t AuEq (165.84 Au and 16.07 Ag) over 8.00 meters (see news release dated January 13, 2025). More details on the QA/QC protocol can be found in the section titled “QA/QC Protocol” below.
  • The best hole drilled to date from the Big Bulk Zone, previously reported as the volcanic wedge zone, is GD-24-291 that assayed 1.97 g/t AuEq (1.92 Au and 1.85 Ag) over 33 meters (see news release dated August 31, 2026). This zone is composed of dense networks of thin mineralized veinlets interpreted to represent distributed fractures filled by mineralized fluids within structural interaction damage zones developed around the Bonanza–Golden Gate junctions. More details on the QA/QC protocol can be found in the section titled “QA/QC Protocol” below.
  • The best hole drilled to date from the Eocene-aged dykes is GD-22-58 that assayed 12.03 g/t AuEq (11.84 g/t Au and 15.61 g/t Ag) over 10.00 meters including 19.91 g/t AuEq (19.62 g/t Au and 25.61 g/t Ag) over 6.00 meters, including 23.82 g/t AuEq (23.47 g/t Au and 30.54 g/t Ag) over 5.00 meters, plus a second separate interval down hole of 8.59 g/t AuEq (8.35 g/t Au and 20.74 g/t Ag) over 5.00 meters (see news release dated March 13, 2025). More details on the QA/QC protocol can be found in the section titled “QA/QC Protocol” below.
  • A study completed by the Colorado School of Mines confirms a new interpretation of the ore forming process at Surebet and suggests a common magmatic source for the high-grade gold system hosted in three distinct rock types. Until this study, researchers and explorers in the Golden Triangle had not recognized the high-grade gold discovery potential in the Eocene-aged dykes (see news release March 13, 2025), which is showing the potential that these discoveries could be a geological breakthrough in the Golden Triangle of British Columbia.
  • Based on positive grassroots exploration and drill results in recent years, Goliath now controls 91,518 hectares (226,146 acres), inclusive of 56 kilometers of the Red Line geologic trend providing for additional discovery potential.
  • The Golddigger Property is located adjacent to tidewater with a barge route to Prince Rupert (190 km south) and close to existing infrastructure including the town of Kitsault proximal to a permitted mine site on private property.

About Golddigger Property

The Golddigger Property is 100% owned and covers an area of 91,518 hectares in a highly prospective geological setting of the Eskay Rift, within 3 kilometers of the Red Line in the Golden Triangle of British Columbia. This area has hosted some of Canada’s greatest gold mines including Eskay Creek, Premier and Snip. Other significant and well-known deposits in the Golden Triangle include Brucejack, Copper Canyon, Galore Creek, Granduc, KSM, Red Chris, and Schaft Creek. Goliath controls 56 kilometers of the Red Line which is a geologic contact between Triassic age Stuhini rocks and Jurassic age Hazelton rocks used as key markers when exploring for gold-copper-silver mineralization.

The Surebet discovery has shown predictable continuity and good metallurgy with gold recoveries of 92.2% from gravity and flotation at a 327-micrometer crush, including 48.8% recovery of free gold from gravity alone (no cyanide required to recover the gold). The metallurgical testing completed to date shows no presence of deleterious elements (see news release dated March 1, 2023).

The Property is in a well positioned location in close proximity to the communities of Alice Arm and Kitsault where there is a permitted mill site on private property. It is situated adjacent to tide water with direct barge access to Prince Rupert (190 kilometers via the Observatory inlet/Portland inlet). The town of Kitsault is accessible by road (190 kilometers from Terrace, 300 kilometers from Prince Rupert) and has a barge landing, dock, and infrastructure capable of housing at least 300 people, including high-tension power.

Additional infrastructure in the area includes the Dolly Varden Silver Mine Road (only 7 kilometers to the East of the Surebet discovery) with direct road access to Alice Arm barge landing (18 kilometers to the south of the Surebet discovery) and high-tension power (25 kilometers to the east of Surebet discovery). The city of Terrace (population 16,000) provides access to railway, major highways, and airport with supplies (food, fuel, lumber, etc.), while the town of Prince Rupert (population 12,000) is located on the West Coast of British Columbia and houses an international container seaport also with direct access to railway and an airport.

Qualified Person

Mr. Rein Turna P. Geo is the qualified person as defined by National Instrument 43-101, for Goliath Resources Limited projects, and supervised the preparation of, and has reviewed and approved, the technical information in this release. Mr. Turna is an Independent Director of the Company.

About CASERM (Center to Advance the Science of Exploration to Reclamation in Mining)

Goliath Resources is a paying member and active supporter of the Center to Advance the Science of Exploration to Reclamation in Mining (CASERM), which is one of the world’s largest research centers in the mining sector. CASERM is a collaborative research venture between Colorado School of Mines and Virginia Tech that is supported by a consortium of mining and exploration companies, analytical instrumentation and software companies, and federal agencies aiming to transform the way geoscience data is acquired and used across the mining value chain. The center forms part of the I-UCRC program of the National Science Foundation. Research focuses on the integration of diverse geoscience data to improve decision making across the mine life cycle, beginning with the exploration for subsurface resources continuing through mine operation as well as closure and environmental remediation. Over the past three years, Goliath Resources’ membership in CASERM has allowed a high level of research to be performed on the Surebet Discovery.

About Goliath Resources Limited

Goliath Resources is an explorer of precious metals projects in the highly prospective Golden Triangle of Northwestern British Columbia. All of its projects are in high quality geological settings and geopolitical safe jurisdictions amenable to mining in Canada. Goliath is a member and active supporter of CASERM which is an organization that represents a collaborative venture between Colorado School of Mines and Virginia Tech. In 2025, Goliath completed its largest drill program to date for a total of 64,364 meters. It is fully funded for a similar sized drill program in 2026. The Company’s key strategic cornerstone shareholders include Crescat Capital, a Global Commodity Group (Singapore), McEwen Inc. (NYSE: MUX) (TSX: MUX), Waratah Capital Advisors, Rob McEwen, Eric Sprott and Larry Childress.

For more information please contact:

Goliath Resources Limited
Mr. Roger Rosmus
Founder and CEO
Tel: +1.416.488.2887
roger@goliathresources.com
www.goliathresourcesltd.com

Disclaimer

The reader is cautioned that grab samples are spot samples which are typically, but not exclusively, constrained to mineralization. Grab samples are selective in nature and collected to determine the presence or absence of mineralization and are not intended to be representative of the material sampled.

Quality Assurance / Quality Control (QA/QC) Protocol

Core Samples Handling & Sampling

Oriented HQ-diameter or NQ-diameter diamond drill core from the drill program is placed in core boxes by the drill crew contracted by the Company. Core boxes are transported by helicopter to the staging area and then transported by truck to the core shack. The core is then re-orientated, meterage blocks are checked, meter marks are labelled, Recovery and RQD measurements taken, and primary bedding and secondary structural features including veins, dykes, cleavage, and shears are noted and measured. The core is then described and transcribed in MX DepositTM. Drill holes were planned using Leapfrog GeoTM and QGISTM software and data from the 2017-2025 exploration programs. Drill core containing quartz breccia, stockwork, veining and/or sulphide(s), or notable alteration is selectively sampled in lengths of 0.5 to 1.5 meters. Samples are selected from continuous intervals of mineralization and/or other relevant geological features, including shoulder samples that extend for 3 meters into adjacent unmineralized and/or unaltered country rock. Along barren core intervals devoid of mineralization or significant geological features, one 1 meter sample is collected every ten meters. Core samples are cut lengthwise in half: one-half remains in the box and the other half is inserted in a clean plastic bag with a sample tag. The bagged samples are then weighed and secured with a zip tie. Certified reference materials (CRMs), blanks and duplicates are added in the sample stream at a rate of 10%. To ensure analytical anonymity, CRM identification labels are removed prior to submission to the laboratory. Additional out-of-sequence blanks are introduced immediately following core samples that contain visible gold to the naked eye (VG-NE) or visibly high-grade sulphide mineralization.

Surface Samples Handling & Sampling

Grab, channels, chip and talus samples were collected by foot with helicopter assistance. Prospective areas included, but were not limited to, proximity to MINFile locations, placer creek occurrences, regional soil anomalies, and potential gossans based on high-resolution satellite imagery. The rock grab and chip samples were extracted using a rock hammer, or hammer and chisel to expose fresh surfaces and to liberate samples weighing anywhere between 0.5 and 5.0 kilograms. All sample sites were flagged with biodegradable flagging tape and marked with the sample number. All sample site locations were recorded using handheld GPS units (accuracy 3-10 meters) and sample ID, easting, northing, elevation, type of sample (outcrop, subcrop, float, talus, chip, grab, etc.) and a description of the rock were recorded on all-weather paper. Samples are then inserted in a clean plastic bag with a sample tag for transport and shipping to the geochemistry lab. QA/QC samples including blanks, certified reference materials, and duplicate samples are inserted regularly into the sample sequence at a rate of 10%.

Samples Analysis

All samples are transported in rice bags sealed with numbered security tags. The rice bags are transported from the core shacks to the MSALABS facilities in Terrace, BC. MSALABS is certified with both AC89-IAS and ISO/IEC Standard 17025:2017. The core samples undergo preparation via drying, crushing to ~70% of the material passing a 2 mm sieve and riffle splitting. The sample splits are weighed and transferred into plastic jars, each containing between 300 g and 500 g of crushed sample material. A 250 g split is pulverized to ensure at least 85% of the material passes through a 75 µm sieve. The crushed samples are transported to the MSALABS PhotonAssayTM facility in Prince George, where gold concentrations are quantified via photon assay analysis (method CPA-Au1). Samples that result in gold concentrations ≥5 ppm are analyzed to extinction. Photon assay uses high-energy X-rays (photons) to excite atomic nuclei within the jarred samples, inducing the emission of secondary gamma rays, which are measured to quantify gold concentrations. The assays from all jars are combined on a weight-averaged basis. Multielement analyses are carried out at the MSALABS facilities in Surrey, BC, where 250 g of pulverized splits are analyzed via IMS-230 and ICF6xx methods. The IMS-230 method uses 4-acid digestion (a combination of hydrochloric, nitric, perchloric and hydrofluoric acids) followed by inductively coupled plasma emission spectrometry to quantify concentrations of 48 elements. Samples with over-limit results for Ag, Cu, Pb and Zn undergo ore-grade analysis via the ICF-6xx method (where ‘xx’ denotes the target metal). This method employs 4-acid digestion followed by inductively coupled plasma emission spectrometry.

Gold Equivalent (AuEq) Calculation

Gold Equivalent (AuEq) values are provided for comparative purposes only and do not include metal recovery factors given that known metallurgical recoveries are only based on preliminary test work and may not be representative of all mineralization styles or zones. Gold Equivalent (AuEq) metal values are calculated using: 4,222.08 Au USD/oz, Ag 67.76 USD/oz, Cu 6.43 USD/lbs, Pb 1,967.13 USD/ton and Zn 3,578.25 USD/ton (updated on August 4, 2026) using the formula below:

There is potential for economic recovery of gold, silver, copper, lead, and zinc based on other mining and exploration projects in the same Golden Triangle Mining Camp where Goliath’s project is located, such as the Homestake Ridge Gold Project (Auryn Resources Technical Report, Updated Mineral Resource Estimate and Preliminary Economic Assessment on the Homestake Ridge Gold Project, prepared by Minefill Services Inc. Bothell, Washington, dated May 29, 2020). Here, AuEq values were calculated using 3-year running averages for metal price, and included provisions for metallurgical recoveries, treatment charges, refining costs, and transportation. Recoveries for Gold were 85.5%, Silver at 74.6%, Copper at 74.6% and Lead at 45.3%. It will be assumed that Zinc can be recovered with Copper at the same recovery rate of 74.6%. The quoted reference of metallurgical recoveries is not from Goliath’s Golddigger Project, Surebet Zone mineralization, and there is no guarantee that such recoveries will ever be achieved, unless detailed metallurgical work such as in a Feasibility Study can be eventually completed on the Golddigger Project.

Reported Drill Intervals and Assays

Drill core intervals are reported as drill lengths, where the true width is estimated to be 80-90% of the length. The widths of the mineralized intervals were defined to reflect both the assay results and the mineralized veining observed in drill core. Veining constrains the local width of the mineralized zone, while assay results define the grade distribution within that zone. Reported intervals are therefore intended to represent geologically meaningful zone widths at the point of intersection.

The reported assays of drill intervals were calculated as length-weighted average grades using the individual sample assay results and their corresponding sample lengths. The average grade for each interval was determined by dividing the sum of the products of each sample grade and sample length by the total sampled interval length (Σ[grade × sample length] / Σ[sample length]). This method accounts for variations in sample length and provides a representative average grade over the reported interval.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQB Venture Market accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Goliath’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to, among other things, the ability of the Company to complete financings and its ability to build value for its shareholders as it develops its mining properties. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Goliath. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the proposed transactions will occur, or that if the proposed transactions do occur, will be completed on the terms described above.

The forward-looking information contained in this release is made as of the date hereof and Goliath is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

This announcement does not constitute an offer, invitation, or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment.  In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The Magnum Ice Cream Company N.V.

(TMICC or the Company)

Share Purchase – Long Term Incentive Plans

The Company announces that it will enter into forward transactions to acquire up to 6.6 million ordinary shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the ordinary shares represent an amount of approximately €110 million.

The forward transactions will be executed in accordance with the requirements of the EU Market Abuse Regulation and other applicable requirements. It is intended that the ordinary shares will be delivered to the Company’s employee benefit trust.

Further details of the transactions will be provided.

Enquiries  
Media Relations
media.relations-tmicc@magnumicecream.com

Investor Relations
investor.relations-tmicc@magnumicecream.com

About The Magnum Ice Cream Company

The Magnum Ice Cream Company N.V. EURONEXT: MICC/ NYSE: MICC/ LSE: MICC is the world’s leading ice cream business. Home to four of the world’s five largest ice cream brands: Magnum, Ben & Jerry’s, Cornetto and the Heartbrand, our portfolio delights consumers in 80 markets around the world. Headquartered in Amsterdam, The Netherlands, we have a global team of 19,000 employees, a network of 32 factories, 13 R&D centres, and a fleet of three million freezer cabinets. For more information, visit www.corporate.magnumicecream.com. TMICC’s legal entity identifier is 25490052LLF3XH6G9847.

To Nasdaq Copenhagen A/S                                18 November 2026
                                        Announcement no. 79/2026

Announcement of Drawings

Pursuant to S. 24 of the Capital Markets Act, we hereby publish drawings (repayment) for bonds issued by Jyske Realkredit. Please find the data in the attached file.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

For further information about format of data and content of the file we refer to the web site of NASDAQ at www.nasdaqomxnordic.com.

Questions may be addressed to Christian Bech-Ravn, Head of Investor Relations, tel. (+45) 89 89 92 25.

Yours sincerely

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.